Market access

Fishawack Health Expands Value, Evidence and Market Access Capabilities with Acquisition of Consulting Company HEOR Policy Analysis Inc. (PAI)

Fishawack Health Announces Expanded Global Value, Evidence, and Access (VEA) Capability for Biopharmaceutical and Medical Technology Companies, with a Suite of End-to-End Services Covering the Product Lifecycle, Combined with Geographic Reach unmatched.

[Image: The Policy Analysis Inc. leadership team (from left: Derek Weycker, PhD, Partner; Thomas Delea, MSIA, Partner; Chad Rose, Chief Operating Officer; Gerry Oster, PhD, Managing Partner.]

March 3, 2022, London, United KingdomFish health (FH), a leading commercialization partner for biopharmaceutical, medtech and wellness companies, today welcomes US health economics and outcomes research consultancy (HEOR) Policy Analysis Inc. (PAI) as part of its growing Value, Proof, and Access (VEA) capability.

With the addition of PAI, FH now has one of the largest and fastest growing teams dedicated to value, evidence and access, all of which are critical to the commercial success of new products. PAI’s team of over 30 professionals join FH’s growing team of strategy consultants and technical experts. In addition to PAI, the VEA team includes US-based market access consultancy Skysis and global market access consultancy PRMA Consulting, which joined FH in 2020 and 2021, respectively.

Jon Koch, CEO of FH, said: “We are delighted to welcome the PAI and hēRo3 teams to FH. They bring an outstanding reputation and track record of technology-driven innovation. With their expertise, we are uniquely positioned to deliver truly insightful strategic thinking and technical execution to meet the changing demands of payers. These services are essential to help our customers make critical decisions early in product development, mitigating some of the risks associated with bringing new molecules and indications to market.

PAI’s core capabilities include HEOR strategy development, evidence generation planning, economic modelling, real-world evidence and trial-based data analysis, evidence synthesis, and risk assessment. health technology. In 2018, PAI also launched an innovative digital platform, called hero3which streamlined HEOR modeling at many biopharmaceutical companies and helped usher in an era of rapid HEOR analysis for pipeline assets.

Gerry Oster, PhD, managing partner at PAI, will become FH’s new global head of health economics, building on his more than 30 years of experience in HEOR. He said: “When the management teams of FH and PAI first met, the synergies and fit were immediately apparent. It was clear that we not only shared core values ​​as companies, but also a vision of how, together, we could bring significant value to our customers. »

He added, “As hēRo3’s adoption rate continued to accelerate, it became clear to us that we needed the right partner to help us ensure it achieves its full potential. We look forward to being an integral part of FH’s new VEA team, helping the company become a powerful presence in HEOR by leveraging our experience, expertise and innovative digital platform, hēRo3.

FH created VEA, its fourth core capability, to help its customers respond more effectively to the rapidly changing and increasingly complex global market access environment. With its new VEA offering, FH has assembled a comprehensive set of capabilities and services to help its customers effectively meet the increasing demands to prove that new products deliver good value.

In addition to the team’s knowledge and strategic expertise, FH clients will also benefit from its proprietary digital HEOR and market access platforms designed to help biopharmaceutical and medical technology companies make smarter decisions. informed during clinical development, reducing time to market.

David Sykes, Head of VEA at FH, said: “Our new global VEA team will provide best-in-class strategic advice from early development to successful launch and beyond. PAI builds our collective strength and ensures that we are best positioned to help our partners accelerate their go-to-market decisions and time to market.

FH has brought together best-in-class global expertise with multidisciplinary skill sets and in-depth knowledge of HEOR landscapes and payers in Europe, North America and the Asia-Pacific region. Working in conjunction with FH’s 3 other capabilities – medicine, marketing and consulting – the VEA team will play a crucial role in realizing the organization’s vision of creating the connections that improve health.

By making these connections throughout the product and portfolio lifecycle, FH can ensure that its clients gain a rigorous understanding of the evolving needs of an increasingly interconnected network of stakeholders, driving a transparent and agile strategy that meets their needs, from early development to launch and beyond. .

About Fishawack Health

Fishawack Health (FH) is a leading global commercialization partner for the biopharmaceutical, medtech and wellness industries. The future of healthcare is fast and complex, requiring a different approach. Established in 2001, our more than 1,300 healthcare experts combine their knowledge and expertise in our 4 core disciplines: medicine; Marketing; value, evidence and access; and Council.

Working across the entire product and service lifecycle, from R&D to post-launch, we engage our collective strength to solve the complex healthcare challenges of today and tomorrow. We imagine a healthier world and build the connections to get there.

Visit us at www.fishawack.com and follow us on Twitter and LinkedIn.

About Policy Analysis Inc. (PAI)

Policy Analysis Inc. (PAI) is a 45-year-old health economics consulting firm, located in Chestnut Hill, Massachusetts, that is an industry leader in the areas of pharmacoeconomics, outcomes research, quality of life assessment, pharmacoepidemiology and health technology assessment.

Visit us at www.pai2.com and follow us on LinkedIn.

Exclusive HEOR and Market Access platforms of FH and PAI

  • hero3: PAI’s new cloud platform has revolutionized HEOR modeling, especially for pipeline assets. It enables rapid value analyzes for development candidates, enabling more strategic design of clinical development programs and HEOR evidence generation plans.
  • PRMA® health check: A digital application driving a systematic and robust assessment of market access risks and opportunities across the asset portfolio.
  • PRMA Navigator®: A platform created to help biopharma customers shorten time to market by allowing affiliates to provide multiple high quality ETS and other payer submissions.
  • PRMA Tracker®: A digital tool designed to help clients stay informed with cutting-edge market information critical to payer assessment and HTA strategy.
  • PRMA Access Accelerator®: The app provides expert insights that inform product development, from early portfolio investment decisions through late-stage market access planning and testing.

Contact Fishawack Health

Natasha Cowan

Corporate Communications Manager

[email protected]

IAP contact

Daniel J. McIntyre

Major

[email protected]

Advisors involved in this transaction included:

KPMG acted on behalf of Fishawack Health for financial and tax due diligence; Sheppard Mullin and Allen & Overy provided legal support; and EY provided tax structuring advice. Arent Fox acted on behalf of PAI for legal counsel. Edgemont Partners provided advice and financial support.